Related Experiment Videos
Administering xCT Inhibitors Based on Circadian Clock Improves Antitumor Effects
Fumiyasu Okazaki1, Naoya Matsunaga2,3, Kengo Hamamura4
1Department of Medical Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan. fokazaki@pha.u-toyama.ac.jp.
Cancer Research
|October 18, 2017
Summary
This study reveals that the Clock gene regulates the expression of xCT, a transporter crucial for cancer cell growth. Timing sulfasalazine treatment with peak xCT expression enhances its anticancer effects, paving the way for chronomodulated chemotherapy.
Area of Science:
- Molecular biology
- Chronobiology
- Cancer research
Background:
- Circadian rhythms, regulated by clock genes, influence physiological processes and drug responses.
- Chronomodulated chemotherapy aims to optimize drug efficacy and minimize side effects by timing treatment according to biological rhythms.
- The cystine-xCT transporter is a target for cancer therapy, with sulfasalazine inhibiting its function.
Purpose of the Study:
- To investigate the transcriptional control of xCT expression by clock genes.
- To determine if the timing of sulfasalazine administration affects its anticancer efficacy.
- To explore the role of the Clock gene in regulating xCT expression and its circadian rhythm.
Main Methods:
- Analysis of xCT expression patterns in relation to circadian rhythms.
- Administration of sulfasalazine at different time points to assess its impact on cancer cells.
- Investigating the direct interaction between the Clock gene and xCT expression.
Main Results:
- Sulfasalazine administration during periods of high xCT expression demonstrated enhanced anticancer effects.
- The Clock gene was identified as a direct inducer of xCT expression.
- The Clock gene regulates the circadian rhythm of xCT expression.
Conclusions:
- The Clock gene plays a critical role in regulating the circadian rhythm of xCT expression.
- Timing chemotherapy with the circadian expression of xCT can improve treatment outcomes.
- These findings support the clinical potential of chronomodulated chemotherapy targeting the xCT transporter.